Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

The Avalanche Approach

Currently, wet age-related macular degeneration is treated with frequent injections of anti-VEGF protein directly into the eyeball. This creates a burden for both patients and physicians, and limits access for those who are not able to comply with frequent visits and injections.

Learn More About The Avalanche Approach:

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

April 22, 2014

– Proceeds will Further Strengthen Avalanche’s Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration –


MENLO PARK, Calif., April 22, 2014 -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and included Deerfield, Adage Capital Management, Redmile Group, Rock Springs Capital, Sabby Capital, as well as an affiliate of Cowen & Company and two undisclosed blue chip health care funds; joining the existing investors. Cowen & Company acted as sole placement agent for the financing.

Read More

Read All Avalanche News